Shares of Jubilant Pharmova fell 2.24% to ₹1,132.50 on Friday after the company announced that the USFDA concluded a pre-approval inspection (PAI) at its solid dosage formulations facility in Roorkee, India, with four observations issued. The previous close was ₹1,158.40.
The stock opened lower and traded in the range of ₹1,131.20 to ₹1,152.20 during the session. At current levels, the company’s market capitalization stands at ₹179.42 billion. Its year range is ₹802.00 to ₹1,309.90, and the average daily traded volume is 371.64K shares. The stock’s P/E ratio is 39.10, and its dividend yield is 0.44%.
According to the exchange filing, Jubilant stated that the company will submit an action plan to address the USFDA’s observations. However, it emphasized that revenue from the Roorkee site contributed less than 1% to the company’s total revenue in the trailing twelve months ending June 2025.
The development has triggered short-term concerns among investors, leading to today’s stock price decline.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
